THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Doman Building Materials Group Ltd. (“Doman” or “the Company”) (TSX: DBM) is pleased to announce that it will report its fourth quarter and full year 2024 financial results for the period ended December 31, 2024, after market hours on Thursday, February 27, 2025. The Company ...

Initiative Drives Operational Efficiencies and Unlocks New Growth Possibilities for Podcasters and Advertisers LOS ANGELES, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PodcastOne (NASDAQ: PODC), a leading publisher and podcast sales network, announced today that it has moved its existing network of programming to hosting service ART19, the podcast distribution and monetization service that lets customers manage content and ad operations in one place. The move streamlines PodcastOne’s hosting capabilities, while drivi ...

Castellammare di Stabia Castellammare di Stabia: Daniel McClory, Executive Chairman of Brera Holdings PLC (center), presents the company’s strategy alongside Juve Stabia executives Castellammare di Stabia: Daniel McClory, Executive Chairman of Brera Holdings PLC (center), presents the company’s strategy alongside Juve Stabia executives Dublin, Ireland, and Milan, Italy, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Brera Holdings PLC (“Brera,” “Brera Holdings” or “the Company”) (Nasdaq: BREA), an Ireland-based, Na ...

-- Accomplished Business and Financial Leader, Laura Brege, Appointed Chair -- -- Paul J. Hastings and Andreas Wicki, PhD Retire from Board of Directors -- PARSIPPANY, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that Laura Brege has been appointed Chair of the Board. Former Chair Paul J. Hastings and Andreas Wicki, PhD. have retired fr ...

Reprocessing of historical electromagnetic data has added greater targeting certainty and will help augment a planned winter 2025 drill program on the Northwest Athabasca Project in Saskatchewan’s Athabasca BasinCALGARY, Alberta, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Global Uranium Corp. (CSE: GURN | OTC: GURFF | FRA: Q3J) (the “Company”) and Forum Energy Metals Corp. (TSX.V: FMC; OTCQB: FDCFF) (“Forum”) are pleased to announce the completion of data compilation and reprocessing of historical electromagnetic (E ...

Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business value TEANECK, N.J., Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as it advances innovations to prevent and treat life-threatening diseases. The expanded agreement aims to deliver greater cost leadership and productivity enha ...

Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic partnership with Zina Biopharmaceuticals, LLC ("Zina") to support all aspects of Jupiter’s upcoming Phase 2a clinical trial for Parkinson’s disease. Under the terms of the agreement, Zina will provide comprehensive services related to the execution of the expl ...

Data confirms ZimVie implants meet critical roughness criteria advantageous for long-term peri-implant healthPALM BEACH GARDENS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced the publication of a detailed scientific study demonstrating the surface texture of ZimVie’s premium implants may help to lower the risk of peri-implant infections when compared to other commercially available implants. The study, titled “ ...

BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has entered into definitive securities purchase agreements with institutional investors for the purchase of an aggregate of 1,261,830 shares of its common stock and accompanying warrants to purchase up to an aggregate of 1,261,830 shares of its common st ...

LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the G ...